Name | Number of supported studies | Average coverage | |
---|---|---|---|
ciliated cell | 19 studies | 53% ± 18% | |
deuterosomal cell | 4 studies | 25% ± 2% |
Insufficient scRNA-seq data for expression of SPATA18 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
kidney | 100% | 812.11 | 89 / 89 | 94% | 29.77 | 846 / 901 |
adrenal gland | 100% | 1070.45 | 258 / 258 | 67% | 7.15 | 154 / 230 |
breast | 95% | 526.33 | 437 / 459 | 70% | 9.17 | 783 / 1118 |
pancreas | 74% | 235.55 | 244 / 328 | 89% | 7.10 | 159 / 178 |
prostate | 99% | 952.41 | 242 / 245 | 62% | 4.41 | 312 / 502 |
thymus | 87% | 308.47 | 570 / 653 | 71% | 9.18 | 432 / 605 |
lung | 98% | 1152.38 | 568 / 578 | 58% | 6.36 | 675 / 1155 |
esophagus | 98% | 507.42 | 1413 / 1445 | 57% | 4.10 | 105 / 183 |
intestine | 93% | 392.47 | 902 / 966 | 59% | 4.38 | 311 / 527 |
uterus | 86% | 559.25 | 146 / 170 | 64% | 6.47 | 294 / 459 |
stomach | 89% | 365.50 | 321 / 359 | 49% | 3.80 | 141 / 286 |
bladder | 81% | 403.48 | 17 / 21 | 52% | 4.09 | 262 / 504 |
skin | 100% | 1315.86 | 1806 / 1809 | 28% | 3.20 | 132 / 472 |
liver | 72% | 252.84 | 162 / 226 | 30% | 2.27 | 121 / 406 |
ovary | 70% | 251.71 | 126 / 180 | 31% | 3.66 | 132 / 430 |
ureter | 0% | 0 | 0 / 0 | 100% | 5.45 | 1 / 1 |
blood vessel | 96% | 707.14 | 1279 / 1335 | 0% | 0 | 0 / 0 |
adipose | 84% | 305.29 | 1008 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 64% | 5.15 | 29 / 45 |
heart | 62% | 203.50 | 538 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 51% | 4.17 | 41 / 80 |
brain | 33% | 202.36 | 868 / 2642 | 17% | 1.91 | 119 / 705 |
spleen | 35% | 79.71 | 85 / 241 | 0% | 0 | 0 / 0 |
muscle | 22% | 59.18 | 174 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 15% | 47.33 | 138 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 14% | 0.78 | 4 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006974 | Biological process | DNA damage response |
GO_0035695 | Biological process | mitophagy by internal vacuole formation |
GO_0035694 | Biological process | mitochondrial protein catabolic process |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0005741 | Cellular component | mitochondrial outer membrane |
GO_0005737 | Cellular component | cytoplasm |
GO_0005739 | Cellular component | mitochondrion |
GO_0042802 | Molecular function | identical protein binding |
GO_0005515 | Molecular function | protein binding |
Gene name | SPATA18 |
Protein name | Mitochondria-eating protein (Spermatogenesis-associated protein 18) Spermatogenesis associated 18 |
Synonyms | MIEAP |
Description | FUNCTION: Key regulator of mitochondrial quality that mediates the repairing or degradation of unhealthy mitochondria in response to mitochondrial damage. Mediator of mitochondrial protein catabolic process (also named MALM) by mediating the degradation of damaged proteins inside mitochondria by promoting the accumulation in the mitochondrial matrix of hydrolases that are characteristic of the lysosomal lumen. Also involved in mitochondrion degradation of damaged mitochondria by promoting the formation of vacuole-like structures (named MIV), which engulf and degrade unhealthy mitochondria by accumulating lysosomes. The physical interaction of SPATA18/MIEAP, BNIP3 and BNIP3L/NIX at the mitochondrial outer membrane regulates the opening of a pore in the mitochondrial double membrane in order to mediate the translocation of lysosomal proteins from the cytoplasm to the mitochondrial matrix. . |
Accessions | ENST00000505320.5 ENST00000295213.9 [Q8TC71-1] ENST00000419395.6 [Q8TC71-2] E7EVV3 D6RGI2 Q8TC71 ENST00000508915.5 |